SHINE Clinical Development Program
SHINE is Dicerna’s clinical development program for belcesiran (DCR-A1AT), an investigational therapy for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease. SHINE currently includes a Phase 2 study called ESTRELLA to evaluate belcesiran. This clinical trial is enrolling adults with AAT deficiency-associated liver disease (AATLD). For more information about the SHINE clinical development program and the ESTRELLA trial, please contact Dicerna at email@example.com or visit: www.clinicaltrials.gov using the identifier NCT04764448.
About belcesiran (DCR-A1AT)
Belcesiran is a subcutaneously administered ribonucleic acid interference (RNAi) therapeutic that is being investigated for the treatment of liver disease in patients with alpha-1 antitrypsin (AAT) deficiency. There are currently no approved therapies to treat AATLD. Belcesiran incorporates Dicerna’s proprietary GalXC™ technology. Belcesiran is designed to target the gene responsible for production of abnormal AAT protein in order to reduce production of this protein in the liver.
The ESTRELLA clinical trial is a Phase 2 research study of belcesiran (DCR-A1AT) in adults with AATLD.
Participating in ESTRELLA
Physicians conducting the ESTRELLA clinical trial are investigators at leading research institutions who specialize in the treatment of AAT deficiency. The trial is being conducted at sites globally.
If you or a loved one has been diagnosed with AAT deficiency-associated liver disease (AATLD) and would like to participate in the ESTRELLA clinical trial or learn more about key participation criteria, please visit www.clinicaltrials.gov using the identifier NCT04764448 or email firstname.lastname@example.org.